Pirfenidone: a potential new therapy for restrictive allograft syndrome?
R Vos, S E Verleden, D Ruttens, E Vandermeulen, J Yserbyt, L J Dupont, D E Van Raemdonck, N De Raedt, O Gheysens, P A De Jong, G M Verleden, B M Vanaudenaerde, R Vos, S E Verleden, D Ruttens, E Vandermeulen, J Yserbyt, L J Dupont, D E Van Raemdonck, N De Raedt, O Gheysens, P A De Jong, G M Verleden, B M Vanaudenaerde
Abstract
This case report describes the evolution of pulmonary function findings (FVC, FEV1 and TLC) and CT features with pirfenidone treatment for restrictive allograft syndrome following lung transplantation. Furthermore, we herein report hypermetabolic activity on (18) F-FDG PET imaging in this setting, which could indicate active fibroproliferation and pleuroparenchymal remodeling. These findings may warrant further investigation.
Keywords: Fibrosis; lung transplantation; pirfenidone; restrictive allograft syndrome.
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.
Source: PubMed